Singapore markets closed

Straits Times Index
3,345.71
+9.12(+0.27%)
S&P 500
5,277.51
+42.03(+0.80%)
Dow
38,686.32
+574.82(+1.51%)
Nasdaq
16,735.02
-2.08(-0.01%)
Bitcoin USD
69,144.40
+1,419.72(+2.10%)
CMC Crypto 200
1,491.27
+23.34(+1.59%)

NTLA Jan 2025 17.500 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

7.70

0.00

(0.00%)

As of 03:59PM EDT. Market open.

GlobeNewswire
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Eight of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with the most severe diseaseSingle dose of NTLA-2002 led to a 98% mean reduction in monthly HAE attack rate, with an average follow-up of over 20 months across a
Zacks
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Simply Wall St.
Earnings Beat: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) just released its quarterly report and things are looking bullish. Results...